Chronic obstructive pulmonary disease with lung cancer: Prevalence, severity, and common pathogenesis

Journal Title: Journal of Cancer Research & Therapy - Year 2016, Vol 4, Issue 1

Abstract

Objectives: To develop a clinical prediction model of contribution of chronic obstructive pulmonary disease (COPD) to the pathogenesis of lung cancer, by reporting the estimated prevalence and severity by GOLD criteria in a single-institution cohort of patients with newly diagnosed lung cancer. Primary objective was investigating the effects of impaired lung function with various histological cell types on crude survival, while considering the initial staging of disease extent. Materials & methods: A total of 441 patients, in this historical cohort from electronic medical records, completed spirometry prior to invasive diagnostic procedures and initial treatment of their lung cancer. All statistical analyses, including ANOVA and survival analysis, were performed using SAS version 9.1 software. Results: Estimated prevalence of COPD was 79.1% (95% confidence interval: 71.3%-82.9%). Lung function as measured by spirometry was a significant predictor of survival time in months (p<0.0001) both with and without adjusting for tumor-cell-type, age, and stage of disease. Median survival was similar (p=0.32) and longer among those patients with normal pulmonary function, those with restrictive disease patterns, and those with COPD–GOLD-1 defects. Median survival was shortest among patients with COPD–GOLD-4 impairment (p=0.001). Those patients with COPD–GOLD-2 and COPD-GOLD-3 impairment levels had intermediate survival times (p=0.003). Conclusions: This investigation suggests that strategies for early detection and slowing the progression of COPD before the development of lung cancer might increase patient survival. As demonstrated in this study, the presence and severity of COPD in lung cancer patients is an independent predictor of survival time, different from the established staging of initial extent of disease.

Authors and Affiliations

Griffin JP, Tolley EA, Zaman MK, Niell HB, Cole FH Jr, Weiman DS

Keywords

Related Articles

Factors associated with first-line bevacizumab use in advanced non-squamous non-small cell lung cancer

Introduction: Bevacizumab was approved for treatment of advanced non-squamous, non-small cell lung cancer (NSCLC) in the US in late 2006. Information on its uptake and patient and tumor factors associated with its use is...

Capecitabine induced hypertriglyceridaemia: An underreported and potentially severe side effect

A 57 year-old-woman, with no previous history of dyslipedemia, developed severe hypertriglyceridemia while being treated with capecitabine for metastatic breast cancer. Capecitabine was not discontinued and serum triglyc...

The first American cancer patient to receive dicycloplatin chemotherapy: A case report

Dicycloplatin (DCP), an effective platinum drug, was developed in China and approved by Chinese FDA in 2012. Its side effects are more bearable than those of cisplatin and carboplatin. The bladder cancer patient presente...

30 years of preventive studies of uterine cervical cancer 1982-2012

Purpose: To show and describe the clinical evolution of cervical cancer screening patients following the protocol established by the University of Padua. Methods: 12,679 patients were examined using Pap smear, colposcopy...

Half-times of irradiation recovery in accelerated partialbreast irradiation: Incomplete recovery as a potentially dangerous enhancer of radiation damage

Purpose: To compare clinical results from accelerated partial breast irradiation with predictions from different half-times of recovery of radiation damage. Method: Three published results of excessive late complications...

Download PDF file
  • EP ID EP541348
  • DOI 10.14312/2052-4994.2016-1
  • Views 78
  • Downloads 0

How To Cite

Griffin JP, Tolley EA, Zaman MK, Niell HB, Cole FH Jr, Weiman DS (2016). Chronic obstructive pulmonary disease with lung cancer: Prevalence, severity, and common pathogenesis. Journal of Cancer Research & Therapy, 4(1), 1-6. https://europub.co.uk/articles/-A-541348